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Personalised medicine is replacing the one-drug-fits-all
approach with many prognostic models incorporating
biomarkers available for risk stratifying patients with
breast cancer, such as the Nottingham Prognostic Index
and Adjuvant! Online and more recently multiparameter
assays, OncotypeDx and Mammaprint.
Evidence of biomarkers having non-proportional
effects have been emerging and therefore violating the
assumption of proportional hazards when performing
Cox regression. A classic example is the risk of recur-
rence after breast cancer depends on the duration of fol-
low-up for estrogen receptor (ER) and progesterone
receptor (PgR) expression status[1]. The gene signature
MammaPrint has also been shown to have possible non-
proportional effects with better prediction of patients at
high risk of early relapse rather than those at risk of
later disease progression[2,3].
A review of existing approaches for the analysis of non-
proportional effects with respect to survival data found
there to be a number of well-developed approaches for
incorporating non-proportional effects but a lack of
application of these approaches in practice. Two key
approaches are the multivariable fractional polynomial
time (MFPT) approach by Sauerbrei et al.[4] and flexible
parametric models proposed by Royston & Parmer[5].
There is a need for more widespread use of flexible
modelling to move away from standard analysis using a
Cox model when the assumption of proportional hazards
is violated. Fully determining the effects of markers in
prognostic studies will help develop novel models for the
selection of patients for appropriate treatments.
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